Logo

BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

Share this

BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

Shots:

  • The P-III CheckMate -498 study involves assessing of Opdivo (nivolumab) + radiation vs temozolomide + radiation in patients with newly diagnosed O6- MGMT-unmethylated GBM
  • The P-III CheckMate -498 (NCT02617589) study demonstrated that it did not meet its 1EPs i.e- OS and is safe for solid tumors
  • Opdivo is PD-1 immune checkpoint inhibitor and is approved as a monothx. as well as combination therapy with Yervoy in the US & EU- currently evaluated in P-III CheckMate -548 (NCT02667587) study assessing Opdivo with SOC- radiation & temozolomide

Ref: BMS | Image: BMS 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions